Follow us on Twitter
twitter icon@FreshPatents


Vaccine patents

      

This page is updated frequently with new Vaccine-related patent applications.




 Methods for producing virus particles with simplified glycosylation of surface proteins patent thumbnailnew patent Methods for producing virus particles with simplified glycosylation of surface proteins
Methods for production of virus particles with simplified glycosylation on structural or surface proteins are provided. When used as targets for vaccine production, the conserved nature of such sites generates vaccines that are less sensitive to viral mutations.
Academia Sinica


 Non-hiv vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against hiv infection patent thumbnailnew patent Non-hiv vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against hiv infection
A new non-hiv vaccine antigen from mycoplasma sp. Permease capable of inducing a mucosal neutralizing protective antibody response against hiv infection, a neutralizing antibody directed to said antigen, and a method for the identification of new antigens from the mucosal microbiota for the development of vaccines against pathogens..
B Cell Design


 Toll-like receptor 8 agonists patent thumbnailnew patent Toll-like receptor 8 agonists
Compounds described herein can be used for therapeutic purposes. The compounds can be tlr agonists, such as tlr8 agonists.

 Poultry virus vaccines that are liquid stable patent thumbnailnew patent Poultry virus vaccines that are liquid stable
The present invention is drawn to liquid stable poultry vaccines that comprise avian virus. The invention is also drawn to the manufacture of such vaccines methods of vaccinating animal subjects with these vaccines..
Intervet Inc.


 T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines patent thumbnailnew patent T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines
The present invention concerns methods and compositions for treatment of hiv infection using a t20 expression vector, such as that shown in seq id no:1 or seq id no:3. The t20 expression vector may be used in a variety of therapeutic applications, such as ex vivo transfection of dendritic cells to induce a host immune response to hiv, localized transfection in vivo in a gene therapy approach to provide longer term delivery of t20, or in vitro production of t20 peptide.
Immunomedics, Inc.


 Respiratory syncytial virus vaccine patent thumbnailnew patent Respiratory syncytial virus vaccine
Described is a vaccine against respiratory syncytial virus (rsv). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the rsv-encoded small hydrophobic (sh) protein.
Universiteit Gent


 Sin nombre virus full-length m segment-based dna vaccines patent thumbnailnew patent Sin nombre virus full-length m segment-based dna vaccines
The invention contemplates a new synthetic, codon-optimized sin nombre virus (snv) full-length m gene open reading frame (orf) that encodes a unique consensus amino acid sequence. The snv orf was cloned into a plasmid to form the first stable recombinant snv full-length m gene that elicits neutralizing antibodies.
The United States Of America, As Rep. By The Sec'y Of The Army, For U.s. Army Medical Research Insti


 Synthetic vaccines against streptococcus pneumoniae type 1 patent thumbnailnew patent Synthetic vaccines against streptococcus pneumoniae type 1
The present invention relates to the total synthesis of saccharide structures contained in the capsular polysaccharide of streptococcus pneumoniae type 1, to glycoconjugates containing said saccharide structures obtained by total synthesis and to use of such glycoconjugates and pharmaceutical compositions thereof in the immunization against diseases associated with bacteria containing said saccharide structures in their capsular polysaccharide, and more specifically associated with streptococcus pneumoniae.. .
Max-planck-gesellschaft Zur FÖrderung Der Wissenschaften E.v.


 Algal based edible vaccines patent thumbnailnew patent Algal based edible vaccines
Provided are edible vaccines including transgenic microalgae expressing at least one exogenous antigen or an intervening organism including the transgenic microalgae. The antigen expressing microalgae are used for oral delivery of the antigen to a target organism in its intact and functional form.
Transalgae Israel Ltd.


 Attenuated live vaccine against mycoplasmal pneumonia of swine (mps) and use thereof patent thumbnailnew patent Attenuated live vaccine against mycoplasmal pneumonia of swine (mps) and use thereof
Disclosed are an attenuated live vaccine against mycoplasmal pneumonia of swine (mps) and use thereof. In the present invention, pathological lung tissues of swine having typical mycoplasma hyopneumoniae (mhp) infection and no obvious other pathogenic infections are screened, and subcultured 100 generations in lungs of newborn rabbits; then, mhp strains are isolated and serially subcultured in a medium; and the mhp strain an306 is obtained by screening a plurality of strains, which is deposited with an accession number: cctcc no.
Jiangsu Academy Of Agricultural Sciences


Neil3 peptides and vaccines including the same

The present invention provides isolated peptides or the fragments derived from seq id no: 45, which bind to an hla antigen and induce cytotoxic t lymphocytes (ctl). The peptides may include the above mentioned amino acid sequence with substitution deletion, or addition of one, two, or several amino acids sequences.
Oncotherapy Science, Inc.

Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants

Small molecule integrin ligand mimetics facilitate integrin-ligand interactions, which may be used to prepare vaccines, adoptive cell therapies, immunotherapies for cancer, and a variety of other conditions. As integrin mediated cell-cell interactions are critical to antigen presentation and effector cell killing, increasing the efficiency of integrin receptor-ligand interactions will stabilize the immune synapse and improve effector functions.
Texas Heart Institute

Bacterial live vector vaccines expressing chromosomally-integrated foreign antigens

Bacterial live vector vaccines represent a vaccine development strategy that offers exceptional flexibility. In the present invention, genes encoding protective antigens of unrelated bacterial, viral, parasitic, or fungal pathogens are expressed in an attenuated bacterial vaccine strain that delivers these foreign antigens to the immune system, thereby eliciting relevant immune responses.
University Of Maryland, Baltimore

Live attenuated catfish vaccine and making

Live attenuated bacteria vaccines against enteric septicemia of fish, especially catfish, and methods related to the same. Mutant strains of the bacteria edwardsiella ictaluri (a pathogenic bacterial strain of enterobacteriaceae) are provided.
Mississippi State University

Immunogenic/therapeutic glycoconjugate compositions and uses thereof

The present disclosure encompasses immunogenic/therapeutic compositions including globo h-klh glycoconjugates (obi-822) and/or therapeutic adjuvants (obi-821/obi-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier.
Obi Pharma, Inc.

Method for porcine circovirus production and pcv2 vaccines

This invention relates to a method for rapid production of pcv2 such that an optimum yield of the virus can be obtained. This invention also relates to the vaccine useful against pcv2 which includes the pcv2 propagated using such a method..
Merial Inc.

Extended-range spray applicator

The disclosure relates to an extended-range spray applicator, and methods of making and use thereof, for dosing vaccines and/or probiotics to avian animals at a distance.. .
Merial Inc.

Nucleic acid vaccines

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (navs) comprising polynucleotide molecules encoding one or more antigens.. .
Moderna Therapeutics, Inc.

Recombinant rift valley fever (rvf) viruses and methods of use

Described herein are recombinant rvf viruses comprising deletions in one or more viral virulence genes, such as nss and nsm. The recombinant rvf viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of rvf virus in livestock and humans.
The Government Of The U.s.a. As Represented By The Secretary Of The Dept. Of Health And Human Servic

Novel vaccines against hpv and hpv-related diseases

Embodiments relate to novel vaccines against human papillomavirus (hpv) and hpv-related diseases, including multiple types of cancers. The hpv vaccines are composed of anti-human dendritic cell (dc) surface receptor antibodies, including cd40, and e6/7 proteins of hpv 16 and 18.
Baylor Research Institute

Vaccines for treatment and prevention of cancer

Provided are compositions useful as therapeutic vaccines (e.g., cancer vaccines), and methods of producing such compositions. The compositions disclosed herein generally employ a stress protein and at least one synthetic peptide, which may be a phosphopeptide or phosphopeptide mimetic, comprising a cancer-specific mutation present in a patient's cancer..
Agenus Inc.

Tumor vascular marker-targeted vaccines

The present invention provides methods of immunizing a subject against a tumor, inhibiting tumor growth, inhibiting tumor recurrence, treating, suppressing the growth of, or decreasing the incidence of a tumor, overcoming tolerance to a tumor vasculature marker (tvm) in a subject comprising the step of administering a vaccine comprising a tvm or a nucleic acid encoding a tvm and related vaccines. The present invention also provides a method of targeting a tumor vasculature in a subject having a tumor comprising the step of contacting said subject with a labeled compound that binds a) a tumor vasculature marker (tvm) or b) a nucleic acid molecule encoding said tvm..
The Trustees Of The University Of Pennsylvania

Cell strain having increased virus production ability and production method therefor

The present invention relates to a cell line having an increased ability to produce virus and a method for preparing thereof, and more particularly, to a cell line that has an increased ability to produce virus, due to the loss of the function of the bst-2 (tetherin) gene, and to a production method thereof. According to the present invention, a cell line lacking the function of the bst-2 gene has an excellent ability to produce virus, compared to a wild-type cell line.
Korea University Research And Business Foundation

Aluminum compounds for use in therapeutics and vaccines

The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition..
Valneva Austria Gmbh

Temperature stable vaccine formulations

vaccine antigen formulations that are stable after undergoing freeze and thaw conditions and methods of preparing the formulations are provided. Methods of using the formulations to prepare vaccine are also provided.
Emergent Product Development Gaithersburg Inc.

Dna vaccine against virus of yellow fever

The present invention relates to vaccines of dna that code for specific viral sequences. The dna vaccines against yellow fever according to the invention are based on the sequence that codes for the yellow fever virus envelope protein (p/yfe).
Fundacao Oswaldo Cruz

Streptococcus pneumoniae capsular polysaccharides and conjugates thereof

The invention relates to activated streptococcus pneumoniae serotype 10a, 22f or 33f polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising streptococcus pneumoniae serotype 10a, 22f or 33f polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them..
Pfizer Inc.

Proline-rich peptides protective against s. pneumoniae

The invention relates to lipopeptides consisting of a peptide chain comprising a parallel coiled-coil domain, a proline-rich peptide antigen, and a lipid moiety, all covalently linked, which aggregate to synthetic virus-like particles. Proline-rich peptide antigens considered contain negatively and positively charged amino acid, and at least 15% of the amino acids are proline.
UniversitÄt ZÜrich

Use of mtor inhibitors to enhance t cell immune responses

It is disclosed herein that treatment of a subject with an mtor inhibitor enhances antigen-specific t cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific t cell response in a subject by administering to the subject a therapeutically effective amount of an mtor inhibitor.
Emory University

Single vial vaccine formulations

The invention provides for thermostable lyophilized formulations, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response, and methods of use thereof. The lyophilized formulations generally comprise an antigen and/or an adjuvant, a metabolizable oil, and a cake-forming excipient..
Infectious Disease Research Institute

Serum antibody assay for determining protection from malaria, and pre-erythrocytic subunit vaccines

Disclosed herein are diagnostic methods and compositions for identifying individuals that are protected against plasmodium falciparum caused malaria. Such methods are particularly useful for determining not only the protective efficacy of pf whole parasite vaccines for individual subjects, but also within populations of vaccinated subjects.
The United States Of America, As Represented By The Secretary, Department Of Health And Human

Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system

The present disclosure relates to surface proteins of moraxella catarrhalis and their ability to interact with epithelial cells via cell-associated fibronectin and laminin, and also to their ability to inhibit the complement system. These surface proteins are useful in the preparation of vaccines.
Arne Forsgren Ab

Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same

Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of hbv core protein, as well as genetic constructs/vectors and vaccines that express said protein sequences. Also provided herein are methods for generating an immune response against hbv using the nucleic acid sequences that are provided..
The Trustees Of The University Of Pennsylvania

Nucleic acid vaccines

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines (navs) comprising polynucleotide molecules encoding one or more antigens.. .
Moderna Therapeutics, Inc.

Prrs virus variant, european prrs virus cdna clone, and uses thereof

The present invention belongs to the field of animal health and provides means to study porcine reproductive and respiratory syndrome (prrs), a viral disease affecting swine, and for the development of vaccines, therapeutics and diagnostics for the prophylaxis, treatment and diagnosis of prrs. In a first consideration, the invention relates to a new prrs virus variant, and, in a second consideration, to a nucleic acid sequence which comprises the genome of an infectious genotype i (eu) prrs virus clone.
Boehringer Ingelheim Vetmedica Gmbh

Methods of treatment of hpv related diseases

The present invention provides methods of mucosal tissue administration of therapeutic hpv vaccines, in a prime-boost regimen, which generated antigen-specific cd8+ t cell-mediated immune responses and the expression of tissue-resident memory t cell (trm) markers on the cd8+ t cells. In some embodiments, the inventive methods employed pngvl4a-sig/e7(detox)/hsp70 dna vaccine and ta-hpv in a prime-boost regimen which shows vaccination in the infected mucosal tissues, including those in the cervicovaginal tract, elicited potent antitumor effects and a more effective local immune response in the tissues and regional lymph node, when compared to intramuscular vaccination.
The Johns Hopkins University

Multiepitope fusion antigens and vaccines and their use in treatment of enterotoxigenic diarrhea

Provided herein are polypeptides comprising up to 9 antigenic elements of etec virulence determinants: 7 cfa adhesins [cfa/i, cfa/ii (cs1, cs2, cs3), cfa/iv (cs4, cs5, cs6)] expressed by the most prevalent and virulent etec strains, and 2 toxins expressed by all etec strains, were genetically fused together for cfa-toxoid fusion with proteins (cfa/i/ii/iv-sta-toxoidlttoxoid). Methods for making these polypeptides and their use in the treatment of etec related disease are also provided..
South Dakota State University

Multivalent breast cancer vaccine

Compositions and methods for immunization against human breast cancer are disclosed. In one embodiment the multivalent antigenic composition is provided comprising immunogenic polypeptides selected from the group consisting of human α-lactalbumin, αs1 casein, β-casein and κ-casein..
The Cleveland Clinic Foundation

Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses

What is described is a novel genetic screen, involving recombinant technology and class i antigen cross-presentation, to search for supraoptimal superagonists of the 27l mart-1 mutant selecting for single amino acid substitution mutants of 27l that activate human antigen-specific ctl clones recognizing the wild-type mart-1.sub.26-35 epitope. Three novel mutant epitopes are identified with superagonist properties that are functionally superior to 27l.

Aquaporin tolerizing vaccines and methods of use thereof

The instant disclosure provides aquaporin dna tolerizing vaccines and methods of using such vaccines for treating individuals having neuromyelitis optica (nmo) and nmo spectrum disorders. Aspects of the methods include administering to the individual, in need thereof, an effective amount of an aquaporin dna tolerizing vaccine to reduce one or more symptoms of nmo or an nmo spectrum disorder.
The Board Of Trustees Of The Leland Stanford Junior University

Low shear microfluidic devices and methods of use and manufacturing thereof

Provided herein relates to systems and methods for producing and using a body having a central channel separated by one or more membranes. The membrane(s) are configured to divide the central channel into at least one mesochannel and at least one microchannel.
President And Fellows Of Harvard College

Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines

The presently disclosed subject matter provides therapeutic methods and compositions for the treatment of bacterial infections caused by streptococcus pneumoniae. In particular, methods are provided for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines in a subject in need thereof comprising administering to the subject an effective amount of an agent that inhibits the interaction between a pd-1 ligand and a pd-1 polypeptide.
Wake Forest University Health Sciences

Single chain il-12 nucleic acids, polypeptides, and uses thereof

The present invention relates to novel single chain interleukin-12 polypeptides. The invention also relates to isolated nucleic acids encoding the single chain interleukin-12 polypeptides, to vectors and cells comprising them, and to their uses, in particular in methods of using single chain il-12 polypeptides, polynucleotides, vectors and cells of the invention for enhancing immune system function, for example as vaccine adjuvants and in the treatment of infections and cancer..
Intrexon Corporation

Novel promiscuous hpv16-derived t helper epitopes for immunotherapy

The present invention relates to novel amino acid sequences of peptides derived from hpv16 that are able to bind to mhc complexes of class ii, and elicit an immune response. The present invention further relates to pharmaceutical products, such as vaccines and t-cells, based on said epitopes..
Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts

Hiv protease inhibitors

The present invention is directed to 2,5,6-substituted morpholine derivatives and their use in the inhibition of hiv protease, the inhibition of hiv replication, the prophylaxis of infection by hiv, the treatment of infection by hiv, and the prophylaxis, treatment, and delay in the onset or progression of aids. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines..
Merck Canada Inc.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Vaccine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.73

file didn't exist2566

469974 - 0 - 55